Popular on TelAve
- Oklahoma and Starlink Local Installers getting it done! / now offering digital menu board installs - 109
- Starlink Local Installers working with state of Minnesota (now offering digital menu board installs)
- Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
- Starlink Local Installers helping Wisconsin stay wired (now offering digital menu board installs)
- BEC Technologies Expands MX-220 5G Industrial Router Series for Edge Connectivity
- T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
- Star Sleep & Wellness Expands to Pearland, Texas — Bringing Life-Changing Sleep Care to More Communities
- Local Fiber Announces Graduation from Samsung Next Startup Program, Marks New Phase of Growth
- From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
- Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
Similar on TelAve
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
- Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
- $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
- $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
- U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
- Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
- MDRN MUSE Expands Insurance Network Coverage to Include Delta Dental & Cigna
Elabscience® Announces Antibody Technology Upgrade and Product Portfolio Enhancement
TelAve News/10880890
HOUSTON - TelAve -- Elabscience®, a leading global biotechnology company dedicated to providing high-quality reagents and services for life science research, today announced a major technological upgrade to its antibody product line. The initiative introduces recombinant rabbit monoclonal antibody technology, representing a significant step forward in antibody innovation, production efficiency, and performance consistency.
This upgrade reflects Elabscience's continued commitment to scientific excellence and innovation, in response to the growing global demand for high-performance and highly reproducible antibody reagents.
Driving Innovation with Recombinant Antibody Technology
With the rapid advancement of recombinant antibody engineering, Elabscience has fully integrated recombinant rabbit monoclonal antibody technology into its R&D and manufacturing processes. This new platform offers outstanding specificity, batch-to-batch consistency, stability, and scalability, addressing long-standing challenges associated with traditional hybridoma-derived antibodies.
"At Elabscience, we continuously strive to improve the scientific reliability of antibody-based research," said Dr. Lan, Director of Antibody Research and Development at Elabscience®. "By introducing recombinant rabbit monoclonal antibodies, we're empowering researchers with higher-quality, more consistent, and more efficient tools to accelerate discovery in fields such as immunology, oncology, and neuroscience."
More on TelAve News
Highlights of the Technology Upgrade
1. Advanced Molecular Design
● Utilizes humanized frameworks with rabbit variable region recombination, reducing heterologous immunogenicity, ideal for long-term in vivo studies.
● Combines phage display library screening with epitope prediction algorithms, enabling the generation of high-affinity antibodies (KD < 10⁻⁹ M) against complex conformational antigens such as GPCRs and ion channels.
2. Enhanced Production Process
● Employs CHO-S suspension cell culture in serum-free media, achieving batch yields over 500 mg, a 20-fold efficiency improvement compared with traditional hybridoma methods.
● Utilizes continuous flow chromatography purification, ensuring endotoxin levels below 0.1 EU/mg and meeting rigorous standards for preclinical research.
3. Stringent Quality Control
● Performs accelerated stability testing (activity retention > 90% after 14 days at 37°C).
● All batches undergo LC-MS peptide mapping and SEC-HPLC purity testing, with monomer content ≥ 98%.
Performance Comparison
Product Type: Anti-β-actin Antibody
Rabbit Polyclonal (Old): Inter-batch CV 12-15%
More on TelAve News
Recombinant Rabbit Monoclonal (New): Inter-batch CV < 3%
Product Type: Anti-PD-1 Antibody
Rabbit Polyclonal (Old): WB detection requires 1:500 dilution
Recombinant Rabbit Monoclonal (New): WB detection possible at up to 1:5000 dilution
Product Type: Anti-GFAP Antibody
Rabbit Polyclonal (Old): Supports IHC application only
Recombinant Rabbit Monoclonal (New): Compatible with IHC/ICC/IF multiple scenarios
These advancements deliver greater sensitivity, reproducibility, and versatility across research applications.
Contact
Elabscience Biotechnology Inc.
🌐 https://www.elabscience.com
📧 orders@elabscience.com
About Elabscience®
Elabscience® develops and produces high-quality reagents, including ELISA kits, antibodies, recombinant proteins, and assay kits to support global research in immunology, oncology, metabolism, and neuroscience.
This upgrade reflects Elabscience's continued commitment to scientific excellence and innovation, in response to the growing global demand for high-performance and highly reproducible antibody reagents.
Driving Innovation with Recombinant Antibody Technology
With the rapid advancement of recombinant antibody engineering, Elabscience has fully integrated recombinant rabbit monoclonal antibody technology into its R&D and manufacturing processes. This new platform offers outstanding specificity, batch-to-batch consistency, stability, and scalability, addressing long-standing challenges associated with traditional hybridoma-derived antibodies.
"At Elabscience, we continuously strive to improve the scientific reliability of antibody-based research," said Dr. Lan, Director of Antibody Research and Development at Elabscience®. "By introducing recombinant rabbit monoclonal antibodies, we're empowering researchers with higher-quality, more consistent, and more efficient tools to accelerate discovery in fields such as immunology, oncology, and neuroscience."
More on TelAve News
- eJoule Inc Participates in Silicon Dragon CES 2026
- HBZBZL Unveils "Intelligent Ecosystem" Strategy: Integrating AI Analytics with Web3 Incubation
- Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
- A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
- Guests Can Save 25 Percent Off Last Minute Bookings at KeysCaribbean's Village at Hawks Cay Villas
Highlights of the Technology Upgrade
1. Advanced Molecular Design
● Utilizes humanized frameworks with rabbit variable region recombination, reducing heterologous immunogenicity, ideal for long-term in vivo studies.
● Combines phage display library screening with epitope prediction algorithms, enabling the generation of high-affinity antibodies (KD < 10⁻⁹ M) against complex conformational antigens such as GPCRs and ion channels.
2. Enhanced Production Process
● Employs CHO-S suspension cell culture in serum-free media, achieving batch yields over 500 mg, a 20-fold efficiency improvement compared with traditional hybridoma methods.
● Utilizes continuous flow chromatography purification, ensuring endotoxin levels below 0.1 EU/mg and meeting rigorous standards for preclinical research.
3. Stringent Quality Control
● Performs accelerated stability testing (activity retention > 90% after 14 days at 37°C).
● All batches undergo LC-MS peptide mapping and SEC-HPLC purity testing, with monomer content ≥ 98%.
Performance Comparison
Product Type: Anti-β-actin Antibody
Rabbit Polyclonal (Old): Inter-batch CV 12-15%
More on TelAve News
- Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
- Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Birmingham SE / Liberty Park
- Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
- Price Improvement on Luxurious Lāna'i Townhome with Stunning Ocean Views
- Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
Recombinant Rabbit Monoclonal (New): Inter-batch CV < 3%
Product Type: Anti-PD-1 Antibody
Rabbit Polyclonal (Old): WB detection requires 1:500 dilution
Recombinant Rabbit Monoclonal (New): WB detection possible at up to 1:5000 dilution
Product Type: Anti-GFAP Antibody
Rabbit Polyclonal (Old): Supports IHC application only
Recombinant Rabbit Monoclonal (New): Compatible with IHC/ICC/IF multiple scenarios
These advancements deliver greater sensitivity, reproducibility, and versatility across research applications.
Contact
Elabscience Biotechnology Inc.
🌐 https://www.elabscience.com
📧 orders@elabscience.com
About Elabscience®
Elabscience® develops and produces high-quality reagents, including ELISA kits, antibodies, recombinant proteins, and assay kits to support global research in immunology, oncology, metabolism, and neuroscience.
Source: Elabscience
0 Comments
Latest on TelAve News
- Women's Everyday Safety Is Changing - The Blue Luna Shows How
- Microgaming Unveils Red Papaya: A New Studio Delivering Cutting-Edge, Feature-Rich Slots
- 5-Star Duncan Injury Group Expands Personal Injury Representation to Arizona
- The End of "Influencer" Gambling: Bonusetu Analyzes Finland's Strict New Casino Marketing Laws
- AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
- TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
- Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
- Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity
- Champagne, Caviar Bumps & Pole Performances — Welcome the New Year Early with HandPicked Social Club
- A New Soul Album: Heart Of Kwanzaa, 7-Day Celebration
- Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
- NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
- Costa Oil - 10 Minute Oil Change Surpasses 70 Locations with Construction of San Antonio, TX Stores — Eyes Growth Via Acquisition or Being Acquired
- LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
- Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- Children Rising Appoints Marshelle A. Wilburn as New Executive Director
- Fairmint CEO Joris Delanoue Elected General Director of the Canton Foundation
- Sleep Basil Mattress Co.'s Debuts New Home Page Showcasing Performance Sleep Solutions for Active Denver Lifestyles
- Bent Danholm Joins The American Dream TV as Central Florida Host